Archive
Here you can find the archive of all Press Releases prior to 2018
Filter by date:
Showing 647 press releases before 2018
-
Faslodex receives US FDA approval as monotherapy for expanded use in breast cancer
-
Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with history of heart attack
-
Lynparza receives additional and broad approval in the US for ovarian cancer
-
US FDA accepts regulatory submission for acalabrutinib and grants Priority Review
-
Acalabrutinib granted Breakthrough Therapy Designation by US FDA for the treatment of patients with mantle cell lymphoma
-
Imfinzi granted Breakthrough Therapy Designation by US FDA for patients with locally-advanced unresectable non-small cell lung cancer
-
Tagrisso significantly improves progression-free survival in the Phase III FLAURA trial for lung cancer
-
AstraZeneca reports initial results from the ongoing MYSTIC trial in Stage IV lung cancer
-
AstraZeneca and Merck establish strategic oncology collaboration
-
H1 2017 Results
Latest articles and press releases
All of our latest press releases and articles are available to explore
Contact us
Gonzalo Viña
Head of Global Media Relations
+44 203 749 5916
Rob Skelding
Director Global Media Relations (Oncology)
+44 203 749 5821
Rebecca Einhorn
Director Global Media Relations (Oncology)
+1 301 398 1802
Matthew Kent
Director Global Media Relations (BioPharmaceuticals)
+44 203 749 5906
Angela Fiorin
Director Global Media Relations (BioPharmaceuticals)
+44 122 334 4690
Jennifer Hursit
Manager Global Media Relations
+44 203 749 5762
Christina Malmberg Hägerstrand
Media Relations Director, Sweden and Nordic-Baltic
+46 855 253 106
